For individuals living with Crohn’s disease or Ulcerative Colitis, finding an effective treatment can sometimes feel like an ongoing journey. While many patients achieve symptom control with conventional medications, others continue to experience flare-ups, treatment failures, or unwanted side effects that impact their daily lives.

As researchers continue to develop new therapies for Inflammatory Bowel Disease (IBD), clinical trials play a critical role in bringing these innovative treatments to patients. However, many people are unfamiliar with how clinical trials work and may feel uncertain about what participation involves.

Questions such as “Will I be safe?”, “What happens during the study?”, and “Can I leave if I change my mind?” are common among potential participants.

Understanding the clinical trial process can help patients make informed decisions about whether participation may be right for them.

At Spoke Research, patients are guided through every stage of the clinical trial journey, from initial screening through to study completion, with patient safety and well-being remaining the highest priority.

Why Clinical Trials Are Essential for IBD Treatment Advances

 

Every medication currently approved for the treatment of Crohn’s disease and Ulcerative Colitis was once evaluated through clinical research.

Clinical trials allow researchers to determine whether new therapies are safe, effective, and capable of improving patient outcomes. Without these studies, medical advances would not be possible.

Research has led to significant breakthroughs in IBD treatment over the past several decades, including the development of biologic therapies and other targeted medications that have transformed disease management for many patients.

Despite these advancements, there remains an ongoing need for new treatment options. Not every patient responds to current therapies, and some may lose response over time.
Clinical trials help address these challenges by investigating new approaches that may offer improved symptom control, longer periods of remission, and better overall quality of life.

Step 1: Identifying Potential Participants

 

Every clinical trial begins by identifying individuals who may qualify for participation.

Each study is designed with specific eligibility criteria that help ensure patient safety and allow researchers to accurately evaluate the treatment being investigated.

These criteria may include factors such as:

• Age
• Type of IBD diagnosis
• Disease severity
• Previous treatment history
• Current medications
• Overall health status

Some studies focus specifically on patients with moderate to severe Crohn’s disease, while others may be designed for individuals living with Ulcerative Colitis.

 

Step 2: Informed Consent

 

Before any study-related procedures take place, patients must provide informed consent.

Informed consent is a fundamental part of ethical clinical research and ensures that participants fully understand the purpose of the study, potential risks, possible benefits, and their rights as participants.

During this process, patients receive detailed information about:

• The purpose of the study
• The treatment being investigated
• Study procedures
• Potential risks and side effects
• Expected duration of participation
• Alternative treatment options
• Confidentiality protections
• The right to withdraw at any time

Patients are encouraged to ask questions and discuss any concerns with the research team before making a decision.

Participation is always voluntary, and individuals can choose not to participate or withdraw from the study at any stage without affecting their future medical care.

Step 3: The Screening Process

 

If a patient appears to be eligible, the next stage involves screening assessments.

The screening phase is one of the most important parts of the clinical trial process because it helps researchers determine whether participation is appropriate and safe.

During screening, patients will undergo:

• Medical history reviews
• Review of current and previous medications
• Physical examinations
• Resting ECG
• Blood tests
• Urine tests
• Stool testing
• Colonoscopy with biopsies
• Imaging studies if required

These assessments provide researchers with valuable baseline information about the patient’s disease activity and overall health.

Screening also helps ensure that participants meet all study requirements before moving forward.

Step 4: Enrollment and Baseline Assessments

 

Once a patient successfully completes screening and signs the informed consent documents, they may be officially enrolled in the study.

At this stage, additional baseline assessments are often performed.

These evaluations provide a detailed picture of the participant’s condition before treatment begins.

Researchers may collect information regarding:

• Disease activity
• Symptom severity
• Quality of life measures
• Laboratory values
• Endoscopic findings
• Biomarkers of inflammation

This baseline data allows researchers to measure how the investigational treatment affects the disease over time.

Step 5: Beginning the Study Treatment

 

Following enrollment, participants begin receiving the study treatment according to the research protocol.

Depending on the specific clinical trial, treatment may involve:

• Investigational medications
• New biologic therapies
• Oral treatments
• Injectable treatments
• Combination treatment approaches

Some studies may compare a new therapy with an existing treatment, while others evaluate a treatment alongside standard care.

Participants receive clear instructions regarding treatment schedules, medication administration, and study requirements.

Throughout the study, the research team carefully monitors adherence to ensure accurate and reliable results.

Step 6: Regular Monitoring and Follow-Up Visits

 

One of the defining features of clinical trial participation is the high level of medical monitoring provided throughout the study.

Participants attend scheduled follow-up visits where researchers assess treatment response and monitor overall health.

These visits may include:

• Symptom assessments
• Physical examinations
• Blood testing
• Stool testing
• Vital sign monitoring
• Medication reviews
• Endoscopic evaluations where necessary
• Assessment of adverse events

Regular monitoring allows researchers to identify potential concerns early and ensure participant safety throughout the study.

For many patients, this level of ongoing observation provides valuable insights into their condition and treatment response.

How Safety Is Monitored Throughout the Trial

 

Patient safety remains the foundation of every clinical trial.

Modern clinical research is conducted under strict regulatory and ethical standards designed to protect participants at every stage.

Before a study can begin, it must receive approval from regulatory authorities and independent ethics committees. Researchers must follow detailed study protocols that outline how patient safety will be monitored and managed.

Safety measures include:

• Continuous monitoring for side effects
• Regular laboratory testing
• Ongoing medical evaluations
• Independent safety oversight
• Strict reporting requirements for adverse events

If any concerns arise during the study, the research team takes immediate action to protect participants.

At Spoke Research, clinical trials are conducted according to internationally recognized Good Clinical Practice (GCP) guidelines and comply with all applicable regulatory requirements.

Step 7: Evaluating Treatment Effectiveness

 

Throughout the study, researchers collect data to determine whether the investigational treatment is achieving its intended goals.

For IBD studies, researchers often evaluate outcomes such as:

• Reduction in inflammation
• Improvement in symptoms
• Clinical remission rates
• Endoscopic healing
• Quality of life improvements
• Reduced reliance on corticosteroids
• Long-term disease control

Because IBD affects individuals differently, researchers analyze information from many participants to understand how the treatment performs across a diverse patient population.

The data collected during clinical trials plays a critical role in determining whether a therapy should move forward toward regulatory approval.

Step 8: Completing the Clinical Trial

 

Once the study reaches its planned conclusion, participants undergo final assessments.

These evaluations may include:

• Physical examinations
• Laboratory testing
• Disease activity assessments
• Review of treatment outcomes
• Quality of life questionnaires

Researchers compare the final results with the baseline data collected at the beginning of the study.

The information gathered from all participants contributes to a broader understanding of the treatment’s safety and effectiveness.

In some cases, patients may be offered opportunities to participate in extension studies that allow continued access to investigational therapies while additional data is collected.

Common Misconceptions About Clinical Trials

 

Many patients hesitate to consider clinical trials because of misconceptions surrounding medical research.

One common myth is that participants are treated as “test subjects” without adequate protection. In reality, modern clinical trials are highly regulated and designed with participant safety as the highest priority.

Another misconception is that patients have no control once enrolled.

In fact, participation is entirely voluntary. Patients can withdraw from a study at any time without penalty and without affecting their access to medical care.

Clinical trials are carefully structured to ensure transparency, informed decision-making, and ongoing support throughout the research process.

How Spoke Research Supports Patients Throughout the Journey

 

At Spoke Research, patient care extends far beyond data collection.

The experienced research team works closely with participants throughout every stage of the clinical trial process, ensuring they feel informed, supported, and comfortable throughout their involvement.

By specializing in clinical trials for Crohn’s disease and Ulcerative Colitis, Spoke Research contributes to the global effort to develop new therapies that may improve outcomes for patients living with IBD.

Through partnerships with leading pharmaceutical companies and research organizations, Spoke Research provides eligible patients with opportunities to participate in studies investigating innovative treatment approaches that may help shape the future of IBD care.

Looking Toward the Future

 

Clinical trials remain one of the most powerful tools for advancing the treatment of Crohn’s disease and Ulcerative Colitis.

Every new therapy begins with research, and every participant contributes to expanding our understanding of these complex conditions.

For patients considering participation, understanding the clinical trial journey can help remove uncertainty and provide confidence in the process.

From screening and enrollment to treatment and follow-up, clinical trials are carefully designed to protect participants while helping researchers develop the next generation of IBD therapies.

As research continues to evolve, clinical trials will remain at the forefront of medical innovation, offering hope for better treatments, improved disease control, and a brighter future for individuals living with IBD.

Spoke Research Contact Information

Telephone: 021 531 6402
Email: info@spokeresearch.co.za
Website: www.spokeresearch.co.za
Address: 15C Park Lane Office Park, 80 Alexandra Road, Pinelands, Cape Town, 7405